Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 4/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13686744 | 1.00 | ALDH1A1 (0.40) | ALDH1A1TSHRPOLBGAANPSR1 | |
| SCHEMBL1640972 | 0.91 | POLB (0.44) | ALDH1A1TSHRPOLBGAANPSR1 | |
| SCHEMBL5021535 | 0.91 | POLB (0.44) | ALDH1A1TSHRPOLBGAANPSR1 | |
| SCHEMBL4886954 | 0.91 | POLB (0.44) | ALDH1A1TSHRPOLBGAANPSR1 | |
| SCHEMBL4885829 | 0.91 | POLB (0.44) | ALDH1A1TSHRPOLBGAANPSR1 | |
| SCHEMBL10262270 | 0.88 | CYP4F2 (0.41) | ALDH1A1TSHRPOLBGAANPSR1 | |
| SCHEMBL247191 | 0.88 | TSHR (0.45) | ALDH1A1TSHRPOLBGAANPSR1 | |
| SCHEMBL12848268 | 0.88 | TSHR (0.45) | ALDH1A1TSHRPOLBGAANPSR1 | |
| SCHEMBL16021740 | 0.87 | ALDH1A1 (0.56) | ALDH1A1TSHRPOLBGAANPSR1 | |
| SCHEMBL20012793 | 0.87 | ALDH1A1 (0.56) | ALDH1A1TSHRPOLBGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-3108886-B1 | CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | SYNTARGA BV (NL) | 2020-06-17 | — | — | EP | disclosed |
| US-20180201577-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180186807-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2018-07-05 | — | — | US | disclosed |
| US-9981939-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9957250-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9862946-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2017-12-14 | — | — | US | disclosed |
| US-9802900-B2 | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9776960-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150133430-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-8952171-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140275176-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140274961-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885TSHR 3518/4885POLB 3494/4885 |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | ALDH1A1 2803/4885TSHR 2993/4885POLB 208/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885TSHR 3518/4885POLB 3494/4885 |
| US-20140275176-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885TSHR 3518/4885POLB 3494/4885 |
| US-20180201577-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885TSHR 3518/4885POLB 3494/4885 |
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885TSHR 3518/4885POLB 3494/4885 |
| US-20140274961-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885TSHR 3518/4885POLB 3494/4885 |
| US-20180186807-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885TSHR 3518/4885POLB 3494/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | ALDH1A1 3700/4885TSHR 721/4885POLB 202/4885 |
| US-20150133430-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885TSHR 3518/4885POLB 3494/4885 |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885TSHR 3518/4885POLB 3494/4885 |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885TSHR 3518/4885POLB 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.